Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading, and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. As the world's largest manufacturer of suppositories and pessaries, Bliss GVS Pharma has established itself as a prominent player in the global pharmaceutical industry. Bliss GVS is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing, and marketing high-quality pharmaceutical formulations at affordable prices for the global market. The company prides itself on being among the world leaders in Suppositories and Pessaries.
The company operates from its registered office at 102 Hyde Park Sakivihar Road, Andheri East, Mumbai, Maharashtra-400072. It has grown to become the only EUGMP certified suppositories manufacturer in India and boasts a research and development centre with over 50 scientists, certified by the Department of Scientific and Industrial Research.
Bliss GVS Pharma manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments. These include anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic products, sold as suppositories, pessaries, capsules, tablets, and syrups. Its extensive portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac.
The company's comprehensive product range also encompasses therapeutic products such as anti-bacterial, anti-dandruff shampoo, amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, anti-biotics, anti-diabetics, anti-diarrheals, anti-emetics, anti-fungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvents, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcer, and anti-ulcerants. Additionally, the portfolio includes analgesics, oral rehydration solutions, antacids, anxiolytics, appetite enhancers, cough syrups, erectile dysfunction treatments, haematinics, hand sanitizers, health supplements, insecticides, treatments for laryngitis, pharyngitis, laxatives, lubricants, mosquito repellents, nasal decongestants, nutritional supplements, moisturizers, prickly heat powder, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements, as well as soaps.
The company demonstrates stable financial performance with a market capitalisation of ₹1,252 crore as of May 2025. On a consolidated basis, Bliss GVS Pharma Ltd reported a profit of ₹25.80 crore on a total income of ₹225.68 crore for the quarter ended 2024. For the full year ended 2024, Bliss GVS Pharma Ltd had posted a profit of ₹81.58 crore on a total income of ₹770.24 crore. The company has delivered a sales growth of 3.27% over the past five years. Notably, the company is almost debt-free, strengthening its financial position.
• FY2024 Performance: Total Income ₹770.24 crore, Net Profit ₹81.58 crore
• Q4 FY2024 Performance: Total Income ₹225.68 crore, Net Profit ₹25.80 crore
• Market Capitalization: ₹1,252 crore (as of May 2025)
• TTM Revenue: ₹809.87 crore
• TTM Net Profit: ₹59.6 crore
The company is led by S R Vaidya as Chairman and Gagan Harsh Sharma as Managing Director. The promoter of Bliss GVS Pharma Ltd is Narsimha Shibroor Kamath, who currently owns 30.78% of the total equity. Promoter holding in Bliss GVS Pharma Ltd has shown an increase, rising to 35.29% as of March 2025 from 34.90% as of June 2024.
Bliss GVS Pharma has made significant progress in expanding its global footprint. A key recent development is the USFDA approval received by Bliss GVS Pharma's partner, Rising Pharma Holdings, for Mesalamine Suppositories 1000 mg. This approval not only enhances Bliss GVS's U.S. portfolio but also reflects its growing R&D capabilities, addressing a niche market valued at USD 29 million by January 2025.
The company has a successful history of strategic achievements, including an investment in 51% share capital of Lifeon Labs Pvt Ltd. and the formation of a new company, Asterisk Lifesciences Limited, as a wholly-owned foreign subsidiary in the UK, aimed at facilitating registrations and marketing efforts in Europe.
Bliss GVS Pharma Ltd's 52-week high share price is ₹184.95, and its 52-week low share price is ₹92.25. Over the last 12 months, Bliss GVS Pharma Ltd's share price moved up by 8.32% on BSE. Looking at the longer term, the share price has moved up by 72.26% on BSE over the last 3 years.
The company's valuation metrics present an attractive picture. The P/B ratio of Bliss GVS Pharma Ltd is 1.19 times as on 05-May-2025, representing a significant 78% discount to its peers' median range of 5.37 times. Similarly, the P/E ratio of Bliss GVS Pharma Ltd is 20.74 times as on 05-May-2025, which is a 41% discount to its peers' median range of 35.15 times.
Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company with a robust global presence, providing products in the antimalarial, antifungal, antibacterial, anti-inflammatory, and antibiotic segments. The company exports its products to various international markets, with its specialized manufacturing capabilities and regulatory approvals in key markets further enhancing its global reach.
The company continues to focus on expanding its product portfolio and international presence. With recent USFDA approvals and strategic investments in research and development, Bliss GVS Pharma is well-positioned to capitalize on growing opportunities in the global pharmaceutical market, particularly in specialized dosage forms where it maintains market leadership. Its debt-free status and discounted valuation metrics suggest a compelling outlook for future growth and value creation.
